(VIANEWS) – The Market ended the session with NYKODE THERAPEUTIC (NYKD.OL) rising 10.72% to kr5.00 on Friday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.93% to kr1,449.45, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
NYKODE THERAPEUTIC’s last close was kr4.52, 81.42% under its 52-week high of kr24.30.
About NYKODE THERAPEUTIC
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, NYKODE THERAPEUTIC has a trailing twelve months EPS of kr-1.26.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -25.99%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 88.5%, now sitting on 6.52M for the twelve trailing months.
Volatility
NYKODE THERAPEUTIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.50%, a negative 1.34%, and a positive 5.07%.
NYKODE THERAPEUTIC’s highest amplitude of average volatility was 2.44% (last week), 4.10% (last month), and 5.07% (last quarter).
Sales Growth
NYKODE THERAPEUTIC’s sales growth is negative 27% for the current quarter and 102.2% for the next.
More news about NYKODE THERAPEUTIC (NYKD.OL).
